Clinical trials: Hepatitis B Infections
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis B who are either treatment-naive, or who have failed lamivudine- or interferon-treatment in the past.
- Trial name
- NCT00487747
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 23 sites in Russia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B, Liver Fibrosis
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B
How to construct a non-invasive, accurate, and convenient method to evaluate the severity of liver fibrosis (LF) is an important general problem in the management of patients with chronic hepatitis B (CHB).
- Trial name
- NCT06779058
- Testing
- MRE, Liver biopsy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shengjing Hospital
Hepatitis B
Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects
The primary objective is to evaluate the safety and tolerability of single oral doses of NCO-48 Fumarate in healthy subjects. The secondary objectives are to evaluate the pharmacokinetic (PK) profile of NCO-48 Fumarate and its…
- Trial name
- NCT04309526
- Testing
- NCO-48 Fumarate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Nucorion Pharmaceuticals, Inc.
Chronic Hepatitis B
HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated
Hepatitis B surface antigen loss/seroconversion, considered to be the ideal outcome of chronic hepatitis B virus (HBV) infection, occurs spontaneously at a low rate in inactive carriers.
- Trial name
- NCT01471535
- Testing
- Pegylated interferon alfa-2a
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis B
Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT05423834
- Testing
- Tenofovir alafenamide, Entecavir
- Where
- Hong Kong
- Volunteers
- 1,800 people
- Sponsor
- Chinese University of Hong Kong
Hepatitis B
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
The investigators evaluated the safety and efficacy of a short lead-in course (8 weeks) of entecavir followed by combination of entecavir plus peginterferon alfa-2a for 40 weeks.
- Trial name
- HBRN (NCT01369199)
- Testing
- Entecavir and peginterferon
- Where
- 21 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B
Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
The purpose of the study is to investigate the long-term safety and the antiviral activity of the optimal doses of LB80380 for additional 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to…
- Trial name
- LB80380 (NCT01242787)
- Testing
- LB80380, Entecavir 0.5 mg
- Where
- 2 sites in China, South Korea
- Volunteers
- 115 people
- Sponsor
- LG Life Sciences
HIV Infection, Hepatitis B
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
Hepatitis B is a contagious virus that can damage a person's liver. It can be prevented by vaccination, but for many HIV-positive people, the vaccines do not help them achieve adequate protection against this virus.
- Trial name
- NCT00106964
- Testing
- Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
- Where
- 11 sites in United States, Brazil and 1 more
- Volunteers
- 371 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Hepatitis B Infection
The Changes of Cytokines During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03210506
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis B, Inadequate Response
Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy
The purpose of this study is to compare the long-term efficacy and safety of entecavir 1.0 mg/d + adefovir 10 mg/d with entecavir 0.5 mg/d + adefovir 10 mg/d for chronic hepatitis B patients with inadequate response to NUC therapy
- Conditions
- Chronic Hepatitis B, Inadequate Response, Nucleos(t)Ide Analogues Treatment
- Trial name
- Dragon-Ex (NCT01829685)
- Testing
- Entecavir, Adefovir
- Where
- 16 sites in China
- Volunteers
- 360 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Hepatitis B
Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)
Entecavir has been one of the option for treatment of lamivudine resistant chronic hepatitis B (CHB). In case of entecavir resistance, adefovir could be used. However, sequential monotherapy may result in multidrug resistance.
- Trial name
- ALTER (NCT01546116)
- Testing
- ADEFOVIR, LAMIVUDINE
- Where
- 9 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Korea University
Chronic HBV Infection (HBeAg Negative)
REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection
REP 2139-Ca is nucleic acid polymer. Nucleic acid polymers have been previously shown to clear serum hepatitis B virus surface antigen (HBsAg) both preclinically (in duck HBV infected ducks) and in human patients and to act…
- Trial name
- NCT02233075
- Testing
- REP 2139-Ca + Pegasys (TM)
- Where
- Moldova
- Volunteers
- 12 people
- Sponsor
- Replicor Inc.
HIV Infections
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to…
- Trial name
- NCT00001119
- Testing
- Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine
- Where
- 12 sites in United States, Australia
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation
The purpose of this study is to determine whether protective anti-HB serum levels are maintained after 6 months of uninterrupted treatment with IGIV-HB Grifols, a new specific hepatitis B immune globulin, in patients having…
- Trial name
- NCT00838071
- Testing
- Specific intravenous anti-hepatitis B immunoglobulin
- Where
- 4 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Instituto Grifols, S.A.
Hepatitis B, Chronic, Hepatitis D, Chronic
A Long Term Follow-up Study of Patients From the REP 301 Protocol
The REP 301 treatment protocol involved the treatment of patients with chronic hepatitis B / hepatitis D co-infection with two agents: REP 2139-Ca and pegylated interferon (peg-IFN).
- Trial name
- NCT02876419
- Where
- Moldova
- Volunteers
- 11 people
- Sponsor
- Replicor Inc.
Hepatitis B
ID HBV Vaccination With Imiquimod in OBI
During the course of chronic hepatitis B infection, patients may undergo hepatitis B surface antigen (HBsAg) seroclearance, resulting in undetectable circulating HBsAg.
- Trial name
- NCT03307902
- Testing
- Imiquimod + ID HBVv, Aqueous + ID HBVv, Imiquimod + IM HBVv
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- The University of Hong Kong
Hepatitis C, Hepatitis B
Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication
The estimated global prevalence of hepatitis C (HCV) infection is approximately 3% (170 million individuals). In Canada there are an estimated 240,000 people infected with HCV.
- Trial name
- NCT00188201
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Chronic Hepatitis
Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
Entecavir (ETV) has shown superior ability to suppress hepatitis B virus (HBV) replication, histology improvement as well as low rate of emergence of resistant mutants.
- Trial name
- NCT01833611
- Testing
- Entecavir
- Where
- 4 sites in Taiwan
- Volunteers
- 130 people
- Sponsor
- National Cheng-Kung University Hospital
Hepatitis B, Chronic, Acute-On-Chronic Liver Failure
Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF
This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.
- Trial name
- NCT04597164
- Testing
- Artificial liver support system
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B
Cohort of Hepatitis B Research of Amsterdam
Hepatitis B is a form of liver disease caused by a DNA-virus, called hepatitis B virus (HBV). Infection can result in an inflammation of the liver parenchyma with various clinical manifestations ranging from an asymptomatic…
- Trial name
- COBRA (NCT01462981)
- Where
- Netherlands
- Volunteers
- 172 people
- Sponsor
- Public Health Service of Amsterdam